Skip to main content

Table 2 Serum ceruloplasmin and 24 h urine copper in all patients with Wilson’s disease during treatment

From: Combined sodium Dimercaptopropanesulfonate and zinc versus D-penicillamine as first-line therapy for neurological Wilson’s disease

Indicator Time Group 1 (N = 93) Group 2 (N = 65/59) P value
Serum ceruloplasmin (mg/L) Baseline 79.34 ± 18.10 84.62 ± 15.75 0.648
8 weeks 82.24 ± 8.24 82.15 ± 15.89 0.965
1 year 81.75 ± 7.63 84.17 ± 9.18 0.147
24-h urinary copper (ug/24 h) Baseline 393.23 ± 213.94 395.16 ± 225.27 0.956
2 weeks 1775.29 ± 665.92 1550.76 ± 540.06 0.026*
4 weeks 1509.21 ± 567.69 1598.01 ± 797.11 0.415
8 weeks 799.36 ± 279.42 874.01 ± 348.16 0.147
1 year 168.77 ± 80.72 176.69 ± 90.64 0.585
  1. Group 1: treated by sodium 2, 3-dimercapto-1-propane sulfonate in combination of zinc; Group 2: treated by D-penicillamine; Compared with Group 2, *P < 0.05; In Group 2: Baseline, 2 and 4 weeks: N = 65, 8 weeks and 1 year: N = 59